Xortx Therapeutics Inc stock is traded at $0.92, with a volume of 31,597. It is down -7.07% in the last 24 hours and down -46.82% over the past month. XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Previous Close:
$0.99
Open:
$0.9411
24h Volume:
31,597
Relative Volume:
1.06
Market Cap:
$1.67M
Revenue:
-
Net Income/Loss:
-$2.77M
P/E Ratio:
-
EPS:
-$2.65
Net Cash Flow:
-$2.69M
1W Performance:
-8.00%
1M Performance:
-46.82%
6M Performance:
-66.67%
1Y Performance:
-68.35%
1-Day Range:
$0.00$0.00
1-Week Range:
$0.89$1.07
52-Week Range:
$0.83$3.60
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS